Prednisolone does not prevent post-herpetic neuralgia. 1987

V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen

In a randomised, double-blind, controlled study of the effect of prednisolone on the development of post-herpetic neuralgia 78 patients with herpes zoster whose pain and exanthema had been present for less than 96 h were given 800 mg acyclovir five times daily for 7 days and prednisolone in a total dose of 575 mg, starting with 40 mg daily in the first week and tapering off over the next 2 weeks. 18 (23%) of the patients had post-herpetic neuralgia at 6 months after the acute zoster, 9 (24.3%) having received prednisolone and 9 (22.5%) placebo. The 95% CI for the difference between the placebo and prednisolone groups in the proportion of patients having pain at 6 months was minus 17% to plus 20%. Prednisolone, however, relieved pain for the first 3 days. The 1-2 week interval between admission and reappearance of pain and development of triggered pain seems to be the time needed to establish neuralgia. Once established, the type and intensity of pain remained largely unaltered.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006562 Herpes Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed) Shingles,Zona,Zoster

Related Publications

V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen
September 1987, Lancet (London, England),
V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen
May 1980, The British journal of dermatology,
V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen
October 1971, Indian journal of dermatology,
V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen
June 2011, Journal of palliative medicine,
V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen
May 1975, Nursing times,
V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen
June 1973, Nursing mirror and midwives journal,
V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen
July 1993, The New Zealand medical journal,
V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen
October 1987, Lancet (London, England),
V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen
January 2012, International journal of general medicine,
V Esmann, and J P Geil, and S Kroon, and H Fogh, and N A Peterslund, and C S Petersen, and J O Ronne-Rasmussen, and L Danielsen
November 1985, Anaesthesia,
Copied contents to your clipboard!